AAAAAA

   
Results: 1-25 | 26-35
Results: 1-25/35
A phase II trial of dual protease inhibitor therapy: Amprenavir in combination with indinavir, nelfinavir, or saquinavir
Authors: Eron, JJ Haubrich, R Lang, W Pagano, G Millard, J Wolfram, J Snowden, W Pedneault, L Tisdale, M
Citation: Jj. Eron et al., A phase II trial of dual protease inhibitor therapy: Amprenavir in combination with indinavir, nelfinavir, or saquinavir, J ACQ IMM D, 26(5), 2001, pp. 458-461
Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome
Authors: DeMasi, RA Graham, NM Tolson, JM Pham, SV Capuano, GA Fisher, RL Shaefer, MS Pakes, GE Sawyerr, GA Eron, JJ
Citation: Ra. Demasi et al., Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome, ADV THER, 18(4), 2001, pp. 163-173
HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health
Authors: Pilcher, CD Shugars, DC Fiscus, SA Miller, WC Menezes, P Giner, J Dean, B Robertson, K Hart, CE Lennox, JL Eron, JJ Hicks, CB
Citation: Cd. Pilcher et al., HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health, AIDS, 15(7), 2001, pp. 837-845
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model
Authors: Chakraborty, H Sen, PK Helms, RW Vernazza, PL Fiscus, SA Eron, JJ Patterson, BK Coombs, RW Krieger, JN Cohen, MS
Citation: H. Chakraborty et al., Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model, AIDS, 15(5), 2001, pp. 621-627
Sexual transmission during the incubation period of primary HIV infection
Authors: Pilcher, CD Eron, JJ Vemazza, PL Battegay, M Harr, T Yerly, S Vom, S Perrin, L
Citation: Cd. Pilcher et al., Sexual transmission during the incubation period of primary HIV infection, J AM MED A, 286(14), 2001, pp. 1713-1714
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir
Authors: Sadler, BM Gillotin, C Lou, Y Eron, JJ Lang, W Haubrich, R Stein, DS
Citation: Bm. Sadler et al., Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir, ANTIM AG CH, 45(12), 2001, pp. 3663-3668
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir- experienced subjects: AIDS Clinical Trials Group protocol 373
Authors: Gulick, RM Smeaton, LM D'Aquila, RT Eron, JJ Currier, JS Gerber, JG Acosta, E Sommadossi, JP Tung, R Snyder, S Kuritzkes, DR Murphy, RL
Citation: Rm. Gulick et al., Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir- experienced subjects: AIDS Clinical Trials Group protocol 373, J INFEC DIS, 183(5), 2001, pp. 715-721
Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva
Authors: Shugars, DC Patton, LL Freel, SA Gray, LR Vollmer, RT Eron, JJ Fiscus, SA
Citation: Dc. Shugars et al., Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva, J DENT RES, 80(2), 2001, pp. 414-420
Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy
Authors: Kuritzkes, DR Shugarts, D Bakhtiari, M Poticha, D Johnson, J Rubin, M Gingeras, TR Kennedy, M Eron, JJ
Citation: Dr. Kuritzkes et al., Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy, J ACQ IMM D, 23(1), 2000, pp. 26-34
Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry
Authors: Pereira, AS Kenney, KB Cohen, MS Hall, JE Eron, JJ Tidwell, RR Dunn, JA
Citation: As. Pereira et al., Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry, J CHROMAT B, 742(1), 2000, pp. 173-183
HIV-1 protease inhibitors
Authors: Eron, JJ
Citation: Jj. Eron, HIV-1 protease inhibitors, CLIN INF D, 30, 2000, pp. S160-S170
Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection (vol 14, pg 671, 2000)
Authors: Eron, JJ Yetzer, ES Ruane, PJ Becker, S Sawyerr, GA Fisher, RL Tolson, JM Shaefer, MS
Citation: Jj. Eron et al., Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection (vol 14, pg 671, 2000), AIDS, 14(9), 2000, pp. 1295-1295
Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection
Authors: Eron, JJ Yetzer, ES Ruane, PJ Becker, S Sawyerr, GA Fisher, RL Tolson, JM Shaefer, MS
Citation: Jj. Eron et al., Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection, AIDS, 14(6), 2000, pp. 671-681
Potent antiretroviral treatment of HIV-infection results in suppression ofthe seminal shedding of HIV
Authors: Vernazza, PL Troiani, L Flepp, MJ Cone, RW Schock, J Roth, F Boggian, K Cohen, MS Fiscus, SA Eron, JJ
Citation: Pl. Vernazza et al., Potent antiretroviral treatment of HIV-infection results in suppression ofthe seminal shedding of HIV, AIDS, 14(2), 2000, pp. 117-121
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370
Authors: Kuritzkes, DR Bassett, RL Johnson, VA Marschner, IC Eron, JJ Sommadossi, JP Acosta, EP Murphy, RL Fife, K Wood, K Bell, D Martinez, A Pettinelli, CB
Citation: Dr. Kuritzkes et al., Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370, AIDS, 14(11), 2000, pp. 1553-1561
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)
Authors: Eron, JJ Murphy, RL Peterson, D Pottage, J Parenti, DM Jemsek, J Swindells, S Sepulveda, G Bellos, N Rashbaum, BC Esinhart, J Schoellkopf, N Grosso, R Stevens, M
Citation: Jj. Eron et al., A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II), AIDS, 14(11), 2000, pp. 1601-1610
Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1 (vol 43, pg 1817, 1999)
Authors: Kashuba, ADM Dyer, JR Kramer, LM Raasch, RH Eron, JJ Cohen, MS
Citation: Adm. Kashuba et al., Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1 (vol 43, pg 1817, 1999), ANTIM AG CH, 44(4), 2000, pp. 1119-1119
Effects of genital tract inflammation on human immunodeficiency virus type1 V3 populations in blood and semen
Authors: Ping, LH Cohen, MS Hoffman, I Vernazza, P Seillier-Moiseiwitsch, F Chakraborty, H Kazembe, P Zimba, D Maida, M Fiscus, SA Eron, JJ Swanstrom, R Nelson, JAE
Citation: Lh. Ping et al., Effects of genital tract inflammation on human immunodeficiency virus type1 V3 populations in blood and semen, J VIROLOGY, 74(19), 2000, pp. 8946-8952
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
Authors: Eron, JJ Smeaton, LM Fiscus, SA Gulick, RM Currier, JS Lennox, JL D'Aquila, RT Rogers, MD Tung, R Murphy, RL
Citation: Jj. Eron et al., The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850), J INFEC DIS, 181(5), 2000, pp. 1622-1628
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
Authors: Gulick, RM Mellors, JW Havlir, D Eron, JJ Meibohm, A Condra, JH Valentine, FT McMahon, D Gonzalez, C Jonas, L Emini, EA Chodakewitz, JA Isaacs, R Richman, DD
Citation: Rm. Gulick et al., 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine, ANN INT MED, 133(1), 2000, pp. 35-39
Discontinuation rates for protease inhibitor regimens containing ritonavir600 mg versus ritonavir 400 mg plus saquinavir 400 mg
Authors: Rublein, JC Eron, JJ Butts, JD Raasch, RH
Citation: Jc. Rublein et al., Discontinuation rates for protease inhibitor regimens containing ritonavir600 mg versus ritonavir 400 mg plus saquinavir 400 mg, ANN PHARMAC, 33(9), 1999, pp. 899-905
Lamivudine in combination with zidovudine stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial
Authors: Kuritzkes, DR Marschner, I Johnson, VA Bassett, R Eron, JJ Fischl, MA Murphy, RL Fife, K Maenza, J Rosandich, ME Bell, D Wood, K Sommadossi, JP Pettinelli, C
Citation: Dr. Kuritzkes et al., Lamivudine in combination with zidovudine stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial, AIDS, 13(6), 1999, pp. 685-694
The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration
Authors: Hoffman, IF Jere, CS Taylor, TE Munthali, P Dyer, JR Wirima, JJ Rogerson, SJ Kumwenda, N Eron, JJ Fiscus, SA Chakraborty, H Taha, TE Cohen, MS Molyneux, ME
Citation: If. Hoffman et al., The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration, AIDS, 13(4), 1999, pp. 487-494
Sexual transmission of HIV: infectiousness and prevention
Authors: Vernazza, PL Eron, JJ Fiscus, SA Cohen, MS
Citation: Pl. Vernazza et al., Sexual transmission of HIV: infectiousness and prevention, AIDS, 13(2), 1999, pp. 155-166
Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual
Authors: Pilcher, CD Eron, JJ Ngo, L Dusek, A Sista, P Gleavy, J Brooks, D Venetta, T DiMassimo, E Hopkins, S
Citation: Cd. Pilcher et al., Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual, AIDS, 13(15), 1999, pp. 2171-2173
Risultati: 1-25 | 26-35